This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veillon, P.
Right arrow Articles by Lunel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veillon, P.
Right arrow Articles by Lunel, F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2003, p. 3212-3220, Vol. 41, No. 7
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.7.3212-3220.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Comparative Evaluation of the Total Hepatitis C Virus Core Antigen, Branched-DNA, and Amplicor Monitor Assays in Determining Viremia for Patients with Chronic Hepatitis C during Interferon Plus Ribavirin Combination Therapy

Pascal Veillon,1 Christopher Payan,1 Gastón Picchio,2 Michèle Maniez-Montreuil,3 Philippe Guntz,4 and Françoise Lunel1*

Laboratoire de Bactério-Virologie, CHU Angers, Angers,1 Etablissement Français du Sang Nord de France, Lille,3 Etablissement Français du Sang Alsace, Strasbourg, France,4 Department of Immunology, The Scripps Research Institute, La Jolla, California2

Received 1 August 2002/ Returned for modification 29 November 2002/ Accepted 18 April 2003

An assay prototype designed to detect and quantify total hepatitis C virus [HCV] core antigen (HCV core Ag) protein in serum and plasma in the presence or absence of anti-HCV antibodies has been recently developed by Ortho-Clinical Diagnostics. The aim of the study was to evaluate the sensitivity, specificity, and reproducibility of the Total HCV core Ag assay in comparison with two quantitative assays for HCV RNA: Quantiplex HCV RNA 2.0 (bDNA v2.0) or Versant HCV RNA 3.0 (bDNA v3.0) assays and the Cobas Amplicor HCV Monitor version 2.0 (HCM v2.0) test. We have studied samples of a well-characterized panel and samples from patients with chronic hepatitis C treated with interferon alone or with ribavirin. We have also compared the kinetics of HCV core Ag and HCV RNA in the follow-up of treated patients. The HCV core Ag assay exhibited linear behavior across samples from different genotypes. The coefficients of variation for intra- and interassay performance were 5.11 and 9.95%, respectively. The specificity of the assay tested in blood donors was 99.5%. Samples from HCV-infected patients showed that the correlation between the HCV core Ag and the two HCV RNA quantitative assays (bDNA and HCM v2.0) was 0.8 and 0.7, respectively. This correlation was maintained across different genotypes of HCV (r2 = 0.64 to 0.94). Baseline HCV core Ag values were significantly lower in sustained responders to interferon (IFN) than in other groups of patients (5.31 log10 [104 pg/ml] versus 5.99 log10 [104 pg/ml]; P < 0.001). In patients treated with IFN or combination therapy, we found an association between a decrease of more than 2 log IU/ml in viral load, undetectable HCV core Ag, and sustained response. Among sustained responders to IFN alone or combination therapy and among relapsers after IFN alone, 84 out of 101 (83.2%) had undetectable HCV core Ag, and 76 out of 96 (79.2%) had a viral load decrease of >=2 log IU/ml, after 1 month of treatment. In conclusion, the Total HCV core Ag assay is a new useful test for the detection of HCV viremia and the monitoring of patients treated with IFN alone or in combination with ribavirin.

* Corresponding author. Mailing address: Service de Bactério-Virologie, CHU ANGERS, 4 rue Larrey, 49033 Angers Cedex, France. Phone: 33 2 41 35 54 93. Fax: 33 2 41 35 41 64. E-mail: fafalulu{at}aol.com or FrLunel-Fabiani{at}chu-angers.fr.

Journal of Clinical Microbiology, July 2003, p. 3212-3220, Vol. 41, No. 7
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.7.3212-3220.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gao, D.-Y., Zhang, X.-X., Hou, G., Jin, G.-D., Deng, Q., Kong, X.-F., Zhang, D.-H., Ling, Y., Yu, D.-M., Gong, Q.-M., Zhan, Q., Yao, B.-L., Lu, Z.-M. (2008). Assessment of Specific Antibodies to F Protein in Serum Samples from Chinese Hepatitis C Patients Treated with Interferon plus Ribavarin. J. Clin. Microbiol. 46: 3746-3751 [Abstract] [Full Text]  
  • Schnuriger, A., Dominguez, S., Valantin, M.-A., Tubiana, R., Duvivier, C., Ghosn, J., Simon, A., Katlama, C., Thibault, V. (2006). Early Detection of Hepatitis C Virus Infection by Use of a New Combined Antigen-Antibody Detection Assay: Potential Use for High-Risk Individuals. J. Clin. Microbiol. 44: 1561-1563 [Abstract] [Full Text]  
  • Pivert, A., Payan, C., Morand, P., Fafi-Kremer, S., Deshayes, J., Carrat, F., Pol, S., Cacoub, P., Perronne, C., Lunel, F. (2006). Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. J. Clin. Microbiol. 44: 417-422 [Abstract] [Full Text]  
  • Konnick, E. Q., Williams, S. M., Ashwood, E. R., Hillyard, D. R. (2005). Evaluation of the COBAS Hepatitis C Virus (HCV) TaqMan Analyte-Specific Reagent Assay and Comparison to the COBAS Amplicor HCV Monitor V2.0 and Versant HCV bDNA 3.0 Assays. J. Clin. Microbiol. 43: 2133-2140 [Abstract] [Full Text]  
  • Gaudy, C., Thevenas, C., Tichet, J., Mariotte, N., Goudeau, A., Dubois, F. (2005). Usefulness of the Hepatitis C Virus Core Antigen Assay for Screening of a Population Undergoing Routine Medical Checkup. J. Clin. Microbiol. 43: 1722-1726 [Abstract] [Full Text]  
  • Krajden, M., Shivji, R., Gunadasa, K., Mak, A., McNabb, G., Friesenhahn, M., Hendricks, D., Comanor, L. (2004). Evaluation of the Core Antigen Assay as a Second-Line Supplemental Test for Diagnosis of Active Hepatitis C Virus Infection. J. Clin. Microbiol. 42: 4054-4059 [Abstract] [Full Text]  
  • Netski, D. M., Wang, X.-H., Mehta, S. H., Nelson, K., Celentano, D., Thongsawat, S., Maneekarn, N., Suriyanon, V., Jittiwutikorn, J., Thomas, D. L., Ticehurst, J. R. (2004). Hepatitis C Virus (HCV) Core Antigen Assay To Detect Ongoing HCV Infection in Thai Injection Drug Users. J. Clin. Microbiol. 42: 1631-1636 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»